Da Prada M, Kettler R, Burkard W P, Lorez H P, Haefely W
Pharmaceutical Research Department, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Acta Psychiatr Scand Suppl. 1990;360:7-12. doi: 10.1111/j.1600-0447.1990.tb05317.x.
A novel class of antidepressants is emerging with considerable therapeutic potential: reversible inhibitors of monoamine oxidase type A (RIMA). Moclobemide (Aurorix) is a representative RIMA. It is a fully and rapidly reversible inhibitor of MAO-A with a correspondingly intermediate duration of action in vivo. It is free of hepatotoxicity and produces a much weaker potentiation of the tyramine pressor effect than the classical irreversible MAO inhibitors. Interaction of MAO inhibitors and monoamine reuptake inhibitors with tyramine is discussed on the basis of experiments in conscious rats. The issue of tyramine content of foods and beverages has been reinvestigated and its relevance for treatment with RIMA antidepressants is discussed. Recently observed antihypoxic (neuroprotective) effects of moclobemide suggest new indications for this compound.
